Latest News

Latest News

An AI Study Without Its Data Is Fiction

An AI Study Without Its Data Is Fiction

Why publish the data at all? My answer comes from my own work. We ran our study not with one AI agent but with several, and later it turned out that the numbers did not match. Without validated AI study data, data that the author answers for in front of the scientific...

read more
Weekly News Roundup | 19 October 2026

Weekly News Roundup | 19 October 2026

Life science news 19 October 2026: three licensing deals, three FDA approvals and two MHRA announcements. Gilead Sciences signed a T-cell engager deal worth up to $1.875bn with Vir Biotechnology. Roche licensed an ALK7 obesity candidate from Rona Therapeutics. The...

read more
Clinical Trial Results 16 October 2026

Clinical Trial Results 16 October 2026

The clinical trial results 16 October 2026 cover neuroendocrine tumours, bladder, head and neck cancers, pulmonary fibrosis and social anxiety. RayzeBio’s RYZ101 met its primary endpoint at interim analysis in gastroenteropancreatic neuroendocrine tumours. The FDA...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

ACTO Achieves Veeva Gold Product Partner Status

ACTO Achieves Veeva Gold Product Partner Status

Validated integrations with Veeva applications help life sciences field teams train, practice, and execute with approved content and real time intelligence Toronto and New York, 2 September 2026 ACTO, uniting human intelligence with empathetic AI in life sciences,...

read more
Huntington Gene Therapy Submission Reaches FDA and MHRA

Huntington Gene Therapy Submission Reaches FDA and MHRA

uniQure filed for regulatory approval of its Huntington’s disease gene therapy on 2 September 2026. The Huntington gene therapy submission went to two agencies. One is the US Food and Drug Administration. The other is the UK Medicines and Healthcare products...

read more
GLP-1 Indications: The 2026 Regulatory Status Map

GLP-1 Indications: The 2026 Regulatory Status Map

The list of approved GLP-1 indications now reaches well beyond weight loss and glycaemic control. Regulators in three major markets have licensed the class across cardiology, nephrology and hepatology. Other conditions carry positive phase 3 data but no licence at...

read more
Avacopan UK Suspension Follows Retracted Trial Data

Avacopan UK Suspension Follows Retracted Trial Data

The avacopan UK suspension took effect on 1 September 2026. The Medicines and Healthcare products Regulatory Agency stopped supply of the medicine to new patients that day. It also signalled its intention to revoke the UK marketing authorisation on 1 March 2027. The...

read more
What a Hospitalist’s Floor Sees That Health AI Doesn’t

What a Hospitalist’s Floor Sees That Health AI Doesn’t

Two rooms that rarely talk I spend my working life in two rooms that almost never talk to each other. The first is the hospital floor, where I care for several thousand patients a year as an attending physician. The second is the conference room, where I evaluate...

read more
Licensing versus Acquisition: How Pharma Chooses

Licensing versus Acquisition: How Pharma Chooses

On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...

read more
ACTO Achieves Veeva Gold Product Partner Status

ACTO Achieves Veeva Gold Product Partner Status

Validated integrations with Veeva applications help life sciences field teams train, practice, and execute with approved content and real time intelligence Toronto and New York, 2 September 2026 ACTO, uniting human intelligence with empathetic AI in life sciences,...

read more
Huntington Gene Therapy Submission Reaches FDA and MHRA

Huntington Gene Therapy Submission Reaches FDA and MHRA

uniQure filed for regulatory approval of its Huntington’s disease gene therapy on 2 September 2026. The Huntington gene therapy submission went to two agencies. One is the US Food and Drug Administration. The other is the UK Medicines and Healthcare products...

read more
GLP-1 Indications: The 2026 Regulatory Status Map

GLP-1 Indications: The 2026 Regulatory Status Map

The list of approved GLP-1 indications now reaches well beyond weight loss and glycaemic control. Regulators in three major markets have licensed the class across cardiology, nephrology and hepatology. Other conditions carry positive phase 3 data but no licence at...

read more
Avacopan UK Suspension Follows Retracted Trial Data

Avacopan UK Suspension Follows Retracted Trial Data

The avacopan UK suspension took effect on 1 September 2026. The Medicines and Healthcare products Regulatory Agency stopped supply of the medicine to new patients that day. It also signalled its intention to revoke the UK marketing authorisation on 1 March 2027. The...

read more
What a Hospitalist’s Floor Sees That Health AI Doesn’t

What a Hospitalist’s Floor Sees That Health AI Doesn’t

Two rooms that rarely talk I spend my working life in two rooms that almost never talk to each other. The first is the hospital floor, where I care for several thousand patients a year as an attending physician. The second is the conference room, where I evaluate...

read more
Licensing versus Acquisition: How Pharma Chooses

Licensing versus Acquisition: How Pharma Chooses

On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

ADHD Management for the Entire Active Day is Within Reach

ADHD Management for the Entire Active Day is Within Reach

When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...

read more
Weekly News Roundup | 31 August 2026

Weekly News Roundup | 31 August 2026

Life science news 31 August 2026: three US approvals, two UK device safety alerts and two licensing deals. Revolution Medicines won approval for a broad RAS-targeted pancreatic cancer drug. AstraZeneca and Ionis presented the full data behind a closely watched heart...

read more
Clinical Trials Roundup | 28 Aug 2026

Clinical Trials Roundup | 28 Aug 2026

Revolution Medicines’ Rasonque receives FDA approval as what the FDA calls the first in class targeted therapy for metastatic pancreatic cancer, Priovant’s Lisraya is cleared as the first oral therapy indicated for dermatomyositis in adults, Johnson & Johnson’s...

read more
From EHR Data to Real-World Evidence: Health IT Meets R&D

From EHR Data to Real-World Evidence: Health IT Meets R&D

For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...

read more

Further News

How AI Is Redefining the Modern Healthcare Consultation

Healthcare in the United States is facing a structural inflection point. Physician burnout remains high. Administrative burdens consume hours that should be spent with patients. Chronic disease rates continue to rise. At the same time, health systems are under...

I’m a Black Gestational Carrier. How People Calculate My Risk Is Wrong

Adding Black maternal-health statistics to data on gestational carriers and calling the sum mine doesn't make it so. The numbers don’t work that way. I’ve carried three pregnancies for other families. I’m also a Black woman. Put those facts beside two well-documented...

Disease Progression Slowing Holds on Function, Misses on Composite

uniQure released four-year results for its Huntington’s disease gene therapy on Tuesday 29 September 2026. The disease progression slowing measured on the composite clinical scale narrowed at 48 months. It missed statistical significance. A second measure, Total...

The Writing Got Cheap. The Checking Did Not

Last month I published a cost analysis with wrong numbers in it. Not rounded wrong. I had taken the wrong price list and the wrong tariff for cache writes, and when I recomputed, the headline figure moved. I issued a corrected version and stopped citing the first one....

The Financial Infrastructure Behind Healthcare Innovation

Healthcare is changing faster than I have ever seen it change, and the revenue cycle has to keep pace. We are talking about AI, new treatments, new technology, new specialties and entirely new ways of delivering care. All of that is exciting, and much of it has the...

Why Complement Therapeutic Research Requires More Than a Single Assay

Complement-targeted drug development requires more than measuring individual proteins. Integrating functional hemolysis assays, carefully selected serum or plasma samples, and multiplex biomarker analysis can provide a more reliable picture of complement activity,...

AstraZeneca Strategic Equity Investment Puts $2bn Into Summit Therapeutics

AstraZeneca’s $2bn strategic equity investment in Summit Therapeutics buys ivonescimab combination access, but only one programme is binding.

    When the Model Is Confident and the Patient Is Not

    It is 2:07 a.m. in the emergency department. The waiting room is thin. The hallway is not. A middle-aged man looks pale. His vitals sit in the green band. A clinical decision support tile on the chart says low risk with a high confidence score. His wife keeps saying...

    China Out-Licensing Deals 2026: The Billion-Dollar Tracker

    In the first half of 2026, China’s innovative drug licensing deals reached $106.3bn, according to VBInsight data published by VCBeat. That total covers inbound and outbound deals. That compares with $135.7bn for the whole of 2025 on the same provider’s count. This...

    What EU PFAS and Microplastics Rules Mean for Cosmetics Formulators

    Cosmetics regulation rarely makes it onto the radar of pharma, biotech, or medical device professionals. It probably should, at least for the next few years. The European Union is in the middle of building two overlapping restriction regimes, one for PFAS and one for...

    Small Cell Lung Cancer Treatment Filing Pulled Ahead of FDA Decision

    Daiichi Sankyo and Merck withdrew a US small cell lung cancer treatment filing for ifinatamab deruxtecan. LSDN examines the UK access gap.

      Overcoming the Delivery Barrier: Systemic Virotherapy and Metastatic Cancer

      The oncology field has made remarkable progress over the past two decades in defining the molecular and immunological drivers of cancer. Modern targeted approaches and immunotherapies have transformed outcomes for many patients, particularly when treating primary or...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.